EUVIMEDEUVIMED entdecken
Crossref

Investigation of Urinary Extracellular Vesicles as Novel and Safe Therapeutics for Autosomal Recessive Polycystic Kidney Disease ( ARPKD )

Yi Huang, Huihua Xing, Ali Osouli, Lisa Guay-Woodford, Eun Ji Chung iD

Journal of Biomedical Materials Research Part A · 2026-02 · 114 (2)

DOI: 10.1002/jbma.70047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, online erschienen am 08.02.2026. Verfasst von Yi Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, Polycystic Kidney, Autosomal Recessive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Innovative Science Accelerator Program (ISAC), NIH R21, U54.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autosomal recessive polycystic kidney disease (ARPKD) is a severe inherited disorder caused primarily by mutations in PKHD1 and in a minority of cases, CYS1 . These genes encode fibrocystin and cystin, respectively. ARPKD typically manifests in infancy with enlarged kidneys, progressive cyst formation, and an estimated peri‐natal high mortality rate of 20%. Given the lack of efficient therapies and the genetic complexity of many rare diseases such as ARPKD, strategies that restore functional proteins defective in the disease may offer a disease‐modifying approach. Urinary extracellular vesicles (uEVs) are naturally secreted by renal and urinary tract cells and contain functional kidney proteins, including fibrocystin and cystin. As such, uEVs may be capable of supplementing these missing proteins and delivering them directly to diseased cells in ARPKD. To investigate the therapeutic potential of uEVs for ARPKD, we first isolated and characterized uEVs from healthy mouse urine by nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and Western blotting for EV markers. PCR confirmed the presence of Cys1 and Pkhd1 mRNAs in uEVs, while cellular uptake was verified by fluorescence microscopy and flow cytometry in collecting duct epithelial cells (mpkCCDc14). In vitro, uEV treatment enhanced Cys1 and Pkhd1 levels in healthy cells, and rescued Cys1 levels in Cys1 ‐deficient cells, derived from Cys1 cpk/cpk ( cpk ) mice. Upon administration in the cpk mouse model of ARPKD, uEV improved the survival rate in cpk mice. Furthermore, in utero administration of uEVs demonstrated accumulation in the fetal kidney and enhanced Cys1 level following intra‐amniotic (IA) administration, highlighting the feasibility of prenatal therapy for the most severe cases of ARPKD that are lethal in utero or within the first 24–48 h after birth. Taken together, our findings reveal that uEVs represent a promising therapeutic modality for ARPKD, capable of restoring deficient CYS1 protein levels and mitigating disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesPolycystic Kidney, Autosomal RecessiveAnimalsMiceHumansFemaleMice, Inbred C57BL

Stichwörter der Autor:innen

extracellular vesiclegene therapykidney diseasenanomedicineprotein therapy

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Southern California, Los Angeles, California, USA.
  • Divisions of Nephrology and Genetics, Research Institute and Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, California, USA.
  • Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Department of Stem Cell Biology and Regenerative Medicine, University of Southern California, Los Angeles, California, USA.

ORCID-Profile: Eun Ji Chung

Förderung

  • Innovative Science Accelerator Program (ISAC)
  • NIH R21
  • U54
  • PKD Foundation Research Grant
  • University of Southern California, Ming Hsieh Institute for Research of Engineering-Medicine for Cancer Research Grant
  • NIDDK NIH HHS
  • NICHD NIH HHS
  • University of Southern California

Zitieren

APA

Huang, Y., Xing, H., Osouli, A., Guay-Woodford, L., & Chung, E. J. (2026). Investigation of Urinary Extracellular Vesicles as Novel and Safe Therapeutics for Autosomal Recessive Polycystic Kidney Disease ( ARPKD ). Journal of Biomedical Materials Research Part A, 114(2). https://doi.org/10.1002/jbma.70047

Vancouver

Huang Y, Xing H, Osouli A, Guay-Woodford L, Chung EJ. Investigation of Urinary Extracellular Vesicles as Novel and Safe Therapeutics for Autosomal Recessive Polycystic Kidney Disease ( ARPKD ). Journal of Biomedical Materials Research Part A. 2026;114(2). doi:10.1002/jbma.70047

BibTeX
@article{Huang2026,
  author = {Huang, Yi and Xing, Huihua and Osouli, Ali and Guay-Woodford, Lisa and Chung, Eun Ji},
  title = {Investigation of Urinary Extracellular Vesicles as Novel and Safe Therapeutics for Autosomal Recessive Polycystic Kidney Disease ( ARPKD )},
  journal = {Journal of Biomedical Materials Research Part A},
  year = {2026},
  volume = {114},
  number = {2},
  doi = {10.1002/jbma.70047}
}
Kostenlos starten →